Preparing EPS submission, i notice most of the forms are expired, that is, beyond their 'use by' dates. Where are up-to-date forms located?
When a compound or composition claim is limited by a particular use, enablement of that claim should be evaluated based on that limitation.
See In re Vaeck, 947 F.2d 488, 495, 20 USPQ2d 1438, 1444 (Fed. Cir. 1991) (claiming a chimeric gene capable of being expressed in any
cyanobacterium and thus defining the claimed gene by its use).
Quite respectfully, is it 'defining the claimed gene by... more »
The zip file containing the March 2014 version of the 9th edition of the MPEP still uses the name of the previous version, ie. e9r-11-2013.zip.
It would be less confusing if the name was consistent with the current version.
There is one place in the MPEP that uses the term "non-analogous" -- MPEP 1504.03.
Every other place in the MPEP uses "nonanalogous."
In the interest of consistency...perhaps the usage in MPEP 1504.03 should be updated.
Quotation from §172 says "...by section 119(e)hall not apply to designs."
The item below refers to claim markings in a reissue application. MPEP 1451 includes a typo in the section reading "Indicia that a continuation reissue application is being filed are . . .".
In bullet 3, strike "1.175" and replace with 1.173:
3. Amendments in proper format per 37 CFR --1.173--
The time for reply in written restriction practice is now 2 months. As per December 2012 patent law treaty, http://www.uspto.gov/patent/initiatives/patent-law-treaty
Thanks to LIE, Adam Queler and Kevin Bechtel for giving me this information.
"On the other hand, should the examiner determine that the elected species is allowable, the examination of the Markush-type claim will be extended. If prior art is then found that anticipates or renders obvious the Markush-type claim with respect to a nonelected species, the Markush-type claim shall be rejected and claims to the nonelected species held withdrawn from further consideration.... more »
Further, the MPEP does not explicitly discuss amino acid sequence restriction in Chapter 800. It would be very helpful if the MPEP discussed restriction and how it applies specifically to amino acid sequences.... more »
> The entry of an amendment (which may not include a new affidavit,declaration, exhibit or other evidence) submitted in an application on appeal is governed by 37 CFR 41.33, not 37 CFR 1.116.
However, 37 CFR 41.33(a) states that:
> Amendments filed after the date of filing an appeal ... and prior to the date a brief is filed ... may be admitted as provided in §1.116 ... .
Furthermore, 1204,... more »
Should §103 of the MPEP be completed with a lead-in section recommending examiners and applicants to frame their analysis on obviousness using the “problem-and-solution approach”?
See the article in ipWatchdog “Could or should the USPTO adopt the EPO problem-and-solution approach for assessing obviousness”.
The materials on which a process is carried out must
be accorded weight in determining the patentability
of a process. Ex parte Leonard, 187 USPQ 122 (Bd.
I just today noticed that 2116 has gone. Why? The change summary** that removed it says "Section removed and reserved" but does not give an explanation. If it was removed for purely logistical reasons, would you please bring... more »
- The text references 37 CFR 1.304 (left column, bottom). However, the AIA removed and reserved that section (https://www.uspto.gov/web/offices/pac/mpep/mpep-9020-appx-r.html#d0e326176). Would you please correct the reference?
- The text does not reference MPEP 1214.07, although 1214.07 does reference 706.07(h), XI. See p. 1200-60 (Nov. 2015). Would you please add the... more »